Maze Therapeutics (MAZE) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 16.7% versus a loss of 5.8%. Rapport Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | RAPP |
|---|---|---|
| Share price | $25.09 | $29.79 |
| Market cap | $1.39B | $1.43B |
| 1-day change | -4.42% | -3.47% |
| YTD return | -36.64% | +1.71% |
| 1-year return | -5.78% | +16.72% |
| EPS (TTM) | $-2.48 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $53.65 | $52.93 |
| 52-week low | $21.95 | $23.75 |
| Distance from 52-week high | -53.23% | -43.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +145.12% | +111.61% |
| Average volume | 560.26K | 359.60K |
| Shares outstanding | 55.55M | 47.98M |
| Employees | 141 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RAPP has outperformed MAZE by 22.5 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
MAZE vs RAPP FAQ
Which is bigger, Maze Therapeutics or Rapport Therapeutics?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.43B compared with $1.39B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, MAZE or RAPP?
RAPP returned +16.72% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Rapport Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics and Biotechnology: Pharmaceutical Preparations for Rapport Therapeutics.